2024
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing
Leader A, Rebbeck T, Oh W, Patel A, Winer E, Bailey L, Gomella L, Lumpkins C, Garraway I, Aiello L, Baskin M, Cheng H, Cooney K, Ganzak A, George D, Halabi S, Hathaway F, Healy C, Kim J, Leapman M, Loeb S, Maxwell K, McNair C, Morgan T, Prindeville B, Soule H, Steward W, Suttiratana S, Taplin M, Yamoah K, Fortune T, Bennett K, Blanding-Godbolt J, Gross L, Giri V. Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing. BMC Public Health 2024, 24: 2533. PMID: 39289635, PMCID: PMC11409532, DOI: 10.1186/s12889-024-20008-8.Peer-Reviewed Original ResearchConceptsSocioecological modelGermline testingHealthcare institutionsCancer genetic testingHereditary cancer implicationsEquity frameworkBlack malesCancer screeningReduce disparitiesBackgroundBlack menCommunity liaisonCommunity stakeholdersMixed-methods approachOvercome barriersImprovement PartnershipCommunity eventsCascade testingModified Delphi modelRate of prostate cancerGenetic testingCancer implicationsEducation programsBlack menEquitable strategiesIncreased engagementBRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients
Cheng H, Shevach J, Castro E, Couch F, Domchek S, Eeles R, Giri V, Hall M, King M, Lin D, Loeb S, Morgan T, Offit K, Pritchard C, Schaeffer E, Szymaniak B, Vassy J, Katona B, Maxwell K. BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients. JAMA Oncology 2024, 10: 1272-1281. PMID: 39052257, DOI: 10.1001/jamaoncol.2024.2185.Peer-Reviewed Original ResearchBRCA1/2 PVCancer riskPoly ADP-ribose polymeraseGenetic testingCancer genetic testingFamilial cancer riskPrimary care cliniciansEvidence of increased riskBRCA1/2-PV carriersMale carriersIncreased genetic testingRisk of breastRisk reductionCancer early detectionCancer-predisposing variantsClinical trial opportunitiesCancer therapy optionsCare cliniciansTargeted risk managementCancer screeningPV carriersHereditary cancerADP-ribose polymeraseGuideline recommendationsEarly cancer detection
2022
Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families
Leader A, Mercado J, Klein A, Hyatt C, Gross L, Brandt R, Giri V. Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families. Journal Of Community Genetics 2022, 13: 547-556. PMID: 35869324, PMCID: PMC9681950, DOI: 10.1007/s12687-022-00603-1.Peer-Reviewed Original ResearchGenetic test resultsProstate cancerGenetic testingDiagnosis of PCaFamily membersClinical trial optionsGermline genetic testingPV/LPVRelevant family membersGenetic testing experiencesImmediate family membersPCa patientsCancer screeningPatientsTrial optionsPrecision therapyGenetic resultsGenetic counselorsTesting experienceThematic analysisCommunication barriersSemi-structured interviewsParticipantsTherapyTesting
2021
Barriers and facilitators of germline genetic evaluation for prostate cancer.
Loeb S, Li R, Sanchez Nolasco T, Byrne N, Cheng H, Leader A, Giri V. Barriers and facilitators of germline genetic evaluation for prostate cancer. Journal Of Clinical Oncology 2021, 39: 28-28. DOI: 10.1200/jco.2021.39.6_suppl.28.Peer-Reviewed Original ResearchCoordination of careProstate cancerGenetic testingChronic Diseases frameworkGuideline-concordant careGermline genetic testingMetastatic prostate cancerGenetic counselingGermline testingLocalized diseasePatient factorsMedical oncologistsTherapeutic optionsCancer screeningPhysicians' knowledgeCurrent guidelinesPhysician educationRecent approvalRadiation oncologistsPractice settingsCancerDisease frameworkThematic saturationProstate Cancer GeneticsGenetic evaluation
2020
Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer
Loeb S, Giri V. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. European Urology Oncology 2020, 4: 1-9. PMID: 33390340, DOI: 10.1016/j.euo.2020.11.011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGermline testingLocalized diseaseMetastatic PCaFamily historyGermline evaluationMetastatic diseaseCurrent guidelinesProstate cancerCancer riskPractice settingsGenetic testingDNA mismatch repair deficiencyManagement of menProstate cancer managementFamily cancer riskEarly-stage PCaMismatch repair deficiencyHereditary cancer riskPathologic featuresHistologic featuresMedical oncologyCancer screeningPCa managementPCa riskConsensus panelKnowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation✰,✰✰
Loeb S, Byrne N, Walter D, Makarov D, Wise D, Becker D, Giri V. Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation✰,✰✰. Cancer Treatment And Research Communications 2020, 25: 100212. PMID: 33091732, DOI: 10.1016/j.ctarc.2020.100212.Peer-Reviewed Original ResearchConceptsGermline testingProstate cancerUrologic practicePCa family historyLocalized prostate cancerMetastatic prostate cancerFamily history criteriaDiverse practice settingsHypothetical case scenariosGermline evaluationU.S. urologistsCancer screeningOvarian cancerPractice patternsFamily historySpecific histologicPCa prognosisNational guidelinesAmerican Urological Association sectionYounger agePractice settingsTesting guidelinesHistory criteriaUrologistsGenetic counselingCancer Screening and Genetic Testing Recommendations for Relatives of Men Undergoing Prostate Cancer Germline Testing: Implications for Practice.
Giri V, Hyatt C, Leader A. Cancer Screening and Genetic Testing Recommendations for Relatives of Men Undergoing Prostate Cancer Germline Testing: Implications for Practice. Journal Of Urology 2020, 204: 1116-1118. PMID: 32926644, DOI: 10.1097/ju.0000000000001150.Peer-Reviewed Original Research
2018
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
Carlo M, Giri V, Paller C, Abida W, Alumkal J, Beer T, Beltran H, George D, Heath E, Higano C, McKay R, Morgans A, Patnaik A, Ryan C, Schaeffer E, Stadler W, Taplin M, Kauff N, Vinson J, Antonarakis E, Cheng H. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precision Oncology 2018, 2018: 1-14. PMID: 30761386, PMCID: PMC6370313, DOI: 10.1200/po.18.00060.Peer-Reviewed Original ResearchGermline genetic testingProstate cancerGenetic testingAdvanced diseaseClinical trialsTreatment selectionProstate Cancer Clinical Trials ConsortiumClinical trial eligibility determinationCascade testingClinical Trials ConsortiumTherapeutic clinical trialsGenetic counselingClinical trial purposesTumor genomic profilingPost-test genetic counselingCancer risk assessmentDNA damage repair genesAppropriate genetic counselingTreatment response predictionWorking GroupClinical benefitPrompt testingCancer screeningGenetic testing practicesTreatment decisions
2017
Exploring Asian Indian and Pakistani views about cancer and participation in cancer genetics research: toward the development of a community genetics intervention
Leader A, Mohanty S, Selvan P, Lum R, Giri V. Exploring Asian Indian and Pakistani views about cancer and participation in cancer genetics research: toward the development of a community genetics intervention. Journal Of Community Genetics 2017, 9: 27-35. PMID: 28660599, PMCID: PMC5752649, DOI: 10.1007/s12687-017-0312-x.Peer-Reviewed Original ResearchAsian Indians/PakistanisCancer riskCancer genetics researchFamily cancer historyHealth care servicesIndians/PakistanisPerceptions of cancerCancer-related researchCancer historyCancer screeningLeading causeMedical recordsCancer stigmaCancer perceptionsFocus groupsCare servicesGenetic testingCancerRecruitment effortsHealth improvementInherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation
Giri V, Obeid E, Gross L, Bealin L, Hyatt C, Hegarty S, Montgomery S, Forman A, Bingler R, Kelly W, Dicker A, Winheld S, Trabulsi E, Chen D, Lallas C, Allen B, Daly M, Gomella L. Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation. JCO Precision Oncology 2017, 1: 1-17. PMID: 34164591, PMCID: PMC8210976, DOI: 10.1200/po.16.00039.Peer-Reviewed Original ResearchFamily historyGenetic counselingMultigene testingEligibility criteriaPrecision therapyFH dataDNA repair genesReferral of menEarly-stage diseaseMultigene panel testingOvarian cancer syndromeStrong family historyCancer genetic evaluationStage/gradeRepair genesDetailed family historyPersonalized genetic counselingProstate cancer predispositionMetastatic diseaseCancer screeningMedical recordsProstate cancerBreast cancerMutation carriersHigh risk
2016
Effects of a randomized trial comparing standard and enhanced counseling for men at high risk of prostate cancer as a function of race and monitoring style
Roussi P, Miller S, Giri V, Obeid E, Wen K, Tagai E, Scarpato J, Gross L, Roy G. Effects of a randomized trial comparing standard and enhanced counseling for men at high risk of prostate cancer as a function of race and monitoring style. Journal Of Health Psychology 2016, 23: 1800-1809. PMID: 28810355, PMCID: PMC5561513, DOI: 10.1177/1359105316671188.Peer-Reviewed Original ResearchConceptsProstate cancer screeningHigh-risk menCancer screeningProstate Cancer Risk Assessment ProgramRoutine prostate cancer screeningCancer Risk Assessment ProgramHealth education sessionsCounseling visitsEnhanced counselingProstate cancerHigh riskEducation sessionsRisk assessment programPsychosocial impactCounseling conditionMenSelf-selected sampleFunction of raceSignificant subsetRiskIntrusive ideationInterventionCounselingScreeningMonitoring styleFamilial prostate cancer
Giri V, Beebe-Dimmer J. Familial prostate cancer. Seminars In Oncology 2016, 43: 560-565. PMID: 27899188, PMCID: PMC6986340, DOI: 10.1053/j.seminoncol.2016.08.001.Peer-Reviewed Original ResearchConceptsFamilial prostate cancerProstate cancer riskProstate cancerHereditary prostate cancerBRCA2 mutationsFamily historyCancer riskNational Comprehensive Cancer Network guidelinesGenetic testingProstate cancer screeningFamily cancer historyProstate cancer patientsEarly-onset diseasePositive family historyFirst-degree relativesClustering of casesNetwork guidelinesColorectal cancerCancer historyCancer patientsCancer screeningCommon tumorsRisk factorsSurrogate markerOvarian cancer
2013
Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer
Handorf E, Crumpler N, Gross L, Giri V. Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer. Journal Of Genetic Counseling 2013, 23: 371-376. PMID: 24310616, PMCID: PMC4028414, DOI: 10.1007/s10897-013-9672-5.Peer-Reviewed Original ResearchConceptsHOXB13 G84E mutationProstate cancerG84E mutationFamily historyProstate cancer screening programsCancer screening programsProstate cancer screeningProstate cancer riskHigh-risk menMen ages 35HOXB13 G84ECancer screeningExact binomial confidence intervalsMutation carriersScreening programAge 35Cancer riskClinical utilityUnaffected menPrevalence estimatesGenetic testingPrevalenceCancerConfidence intervalsGenetic counselingGenetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men
Hughes L, Ruth K, Rebbeck T, Giri V. Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men. Prostate Cancer And Prostatic Diseases 2013, 16: 308-314. PMID: 24061634, PMCID: PMC3865712, DOI: 10.1038/pcan.2013.36.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramAfrican American menHigh-risk menCC/CTProstate cancerCancer diagnosisIL-16Family historyProstate cancer screening strategiesProstate cancer risk assessmentCancer Risk Assessment ProgramIL-16 genotypesLongitudinal screening programCancer screening strategiesProstate cancer screeningTaqMan SNP genotyping assaysProstate cancer developmentPersonalized risk estimatesAfrican AmericansCancer risk assessmentGenetic variantsHazard ratioSNP genotyping assaysCancer screeningScreening program
2011
Rates and predictors of colorectal cancer screening by race among motivated men participating in a prostate cancer risk assessment program
Hall M, Ruth K, Giri V. Rates and predictors of colorectal cancer screening by race among motivated men participating in a prostate cancer risk assessment program. Cancer 2011, 118: 478-484. PMID: 21751189, PMCID: PMC3195866, DOI: 10.1002/cncr.26315.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramCancer Risk Assessment ProgramAfrican American menUptake of CRCPredictors of uptakeCRC screeningLower endoscopyRisk assessment programAmerican menProstate cancerFamily historyFecal occult blood testingFecal occult blood testFox Chase Cancer CenterOccult blood testingColorectal cancer mortalityOccult blood testColorectal cancer screeningMultivariate logistic regressionProstate cancer clinicBlood testsBlood testingCancer CenterCancer mortalityCancer screening
2009
Prostate Cancer Early Detection Program Recruitment Methods and Show Rates in Men at High Risk
Giri V, Coups E, Ruth K, Goplerud J, Raysor S, Kim T, Bagden L, Mastalski K, Zakrzewski D, Leimkuhler S, Watkins-Bruner D. Prostate Cancer Early Detection Program Recruitment Methods and Show Rates in Men at High Risk. Journal Of Urology 2009, 182: 2212-2218. PMID: 19758657, PMCID: PMC2760660, DOI: 10.1016/j.juro.2009.07.021.Peer-Reviewed Original ResearchConceptsHigh riskProstate cancerFamily historyProstate cancer screening studyProstate cancer risk assessmentProstate Cancer Risk Assessment ProgramProstate cancer family historyRecruitment methodsShow ratesCancer Risk Assessment ProgramProstate cancer screeningCancer screening studyEarly Detection ProgramCancer family historyLow socioeconomic statusBlack menCancer risk assessmentMen 35Cancer screeningLow presentation ratesBRCA1/2 mutationsRisk assessment programProgram visitsMore menParticipant demographics
2008
Substantial family history of prostate cancer in black men recruited for prostate cancer screening
Mastalski K, Coups E, Ruth K, Raysor S, Giri V. Substantial family history of prostate cancer in black men recruited for prostate cancer screening. Cancer 2008, 113: 2559-2564. PMID: 18816608, PMCID: PMC2626163, DOI: 10.1002/cncr.23862.Peer-Reviewed Original ResearchConceptsFH of PCaProstate Cancer Risk Assessment ProgramNational Health Interview SurveyProstate cancerFamily historyBlack menCancer Risk Assessment ProgramMore first-degree relativesSelf-reported family historyMore family historyProstate cancer screeningHigh-risk menMen ages 35First-degree relativesHealth Interview SurveyAge-matched sampleSuboptimal screeningCancer screeningBreast cancerScreening programAge 35Colon cancerPCa screeningRisk assessment programCancer